SecBot SecBot
8-K ·Filed Apr 24, 2026

BIO-B

BIO-RAD LABORATORIES, INC.
NEUTRAL
Impact 4/10
Horizonmonths Processed6mo ago SEC0000012208-26-000024
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor future equity grant practices and dilution levels as the increased share reserve provides more flexibility for executive compensation. The routine nature of these shareholder approvals suggests business continuity, but watch for any changes in executive compensation trends in upcoming filings.

DirectionNeutral
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d
BIO-B ▲ +3.31% at T+60d
NEUTRAL call +3.31% · α vs SPY -1.46% · entry $299.45 → $309.37
Entry = T+0 close
Apr 24, 2026
via day close
T+1d
0.00%
call 0.00% · α +0.49%
$299.45
settled 6mo ago
T+5d
0.00%
call 0.00% · α -0.40%
$299.45
settled 6mo ago
T+20d
-10.69%
call -10.69% · α -15.65%
$267.43
settled 5mo ago
T+60d
+3.31%
call +3.31% · α -1.46%
$309.37
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Bio-Rad Laboratories amended its 2017 Incentive Award Plan, increasing the share reserve by 335,000 shares and extending the plan's expiration date to March 18, 2036. This amendment was approved by shareholders at the annual meeting, along with the re-election of all board nominees and ratification of auditors.

Key Facts

  • Shareholders approved an amendment to increase the share reserve under the 2017 Incentive Award Plan by 335,000 shares
  • The plan's expiration date was extended by approximately two years to March 18, 2036
  • All nominated directors were re-elected at the annual meeting
  • Shareholders ratified KPMG LLP as independent auditors for 2026
  • The advisory vote on executive compensation was approved

Financial Impact

The plan amendment increases the share reserve by 335,000 shares for future equity compensation grants

share countequity compensationdilution

Risk Factors

  • Potential for increased share dilution from the additional 335,000 shares now available for grants
  • Governance risk if the expanded equity pool leads to excessive executive compensation

Market Snapshot

Exchange
NYSE
Sector
Laboratory Analytical Instruments

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000012208-26-000024
Document: bio-20260421.htm0000012208-26-000024
Document: 0000012208-26-000024-index-headers.html0000012208-26-000024
Document: 0000012208-26-000024-index.html0000012208-26-000024
Document: 0000012208-26-000024.txt0000012208-26-000024

US Market Status

Market Open — Closes in 3h 32m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 24, 2026